Social media

At #OCT Southeast on 10–11 March, ICON will showcase the operational, scientific and digital expertise that helps biotechs navigate complexity and deliver studies with greater certainty. Visit Booth #37 to speak with o...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in SelectScience® Science explores the evolving NIT landscape, emerging...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in Select Science explores the evolving NIT landscape, emerging regulat...

Join Luke Gregory at #ACDM26 as he explores why artificial intelligence is only one part of a truly effective clinical data science toolkit. Drawing on practical examples, he will show how thoughtful problem assessment, ...

Join Luke Gregory at #ACDM26 as he explores why artificial intelligence is only one part of a truly effective clinical data science toolkit. Drawing on practical examples, he will show how thoughtful problem assessment, ...

Flow cytometry is rapidly evolving - driven by high parameter and spectral technologies, smarter data analytics and global standardisation efforts. This Spotlight hosted by Bioanalysis Zone brings together leading expe...

Flow cytometry is rapidly evolving - driven by high parameter and spectral technologies, smarter data analytics and global standardisation efforts. This Spotlight hosted by Bioanalysis Zone brings together leading expe...

Today on Rare Disease Day, explore how ICON is supporting a global phase 3 clinical trial in Generalised Myasthenia Gravis (gMG), a rare autoimmune disorder affecting an estimated 700,000 people worldwide. By navigatin...

Approximately 5% of the world’s population is affected by a Rare Disease. ICON is committed to raising awareness and generating change for people worldwide living with Rare Diseases, their families and carers. Learn ho...

New qualitative research from ICON explores patient experiences in advanced/metastatic hepatocellular carcinoma, identifying fatigue, weight loss, weakness, appetite reduction, and sleep disturbance as the most frequent ...

New qualitative research from ICON explores patient experiences in advanced/metastatic hepatocellular carcinoma, identifying fatigue, weight loss, weakness, appetite reduction, and sleep disturbance as the most frequent ...

Come along to Rüdiger Kaspera's Learning Lab at ASCPT, where he’ll dive into science and risk based strategies for designing oligonucleotide First‑in‑Human studies - covering toxicity, study design, PK/PD, population se...